Improving treatment intensification to reduce cardiovascular disease risk: a cluster randomized trial

Table 4 Pre- and Post-Intervention Risk Factor Control Rates for Entire Phase Populations, by Study Arm and Priority Level

	Study Facilities (n = 4)			Control Facilities (n = 4)
	PHASE Population Size ¹	Pre-Intervention % in Control ²	Post-Intervention, % in Control ²	PHASE Population Size ¹	Pre-Intervention % in Control ²	Post- Intervention % in Control ²
SBP ≥ 140	72,895	83.5	84.0	54,652	81.7	82.4
LDL-c ≥ 130	67,099	90.2	91.5	49,355	90.1	91.4
A1c ≥ 9%	48,464	90.9	91.0	38,497	90.3	90.7
SBP 130-139^¶	72,895	61.1	62.8	54,652	60.7	62.6
LDL-c 100-129	67,099	71.8	75.3	49,355	71.7	75.5
A1c 7-8.9%	48,464	60.5	58.8	38,497	60.0	58.1

¹ Members identified in Kaiser Permanente Northern California’s PHASE population from 1 year prior to the intervention to 1 year following the intervention, eligible for the priority by virtue of age and comorbidities, and with at least one risk factor measure in each period.
² Control assessed based on latest recorded factor value during each period.

ISSN: 1472-6963